FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare
- PMID: 39909534
- PMCID: PMC11795397
- DOI: 10.1136/bmj-2024-081554
FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare
Erratum in
-
FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare.BMJ. 2025 Feb 17;388:r340. doi: 10.1136/bmj.r340. BMJ. 2025. PMID: 39961614 Free PMC article. No abstract available.
Abstract
Despite major advances in artificial intelligence (AI) research for healthcare, the deployment and adoption of AI technologies remain limited in clinical practice. This paper describes the FUTURE-AI framework, which provides guidance for the development and deployment of trustworthy AI tools in healthcare. The FUTURE-AI Consortium was founded in 2021 and comprises 117 interdisciplinary experts from 50 countries representing all continents, including AI scientists, clinical researchers, biomedical ethicists, and social scientists. Over a two year period, the FUTURE-AI guideline was established through consensus based on six guiding principles—fairness, universality, traceability, usability, robustness, and explainability. To operationalise trustworthy AI in healthcare, a set of 30 best practices were defined, addressing technical, clinical, socioethical, and legal dimensions. The recommendations cover the entire lifecycle of healthcare AI, from design, development, and validation to regulation, deployment, and monitoring.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from European Union’s Horizon 2020 for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. GD owns equity interest in Artrya Ltd and provides consultancy services. JK-C receives research funding from GE, Genetech and is a consultant at Siloam Vision. GPK advises some AI startups such as Gleamer.AI, FLUIDDA BV, NanoX Vision and was the founder of Quantib BV. SEP is a consultant for Circle Cardiovascular Imaging, Calgary, Alberta, Canada. BG is employed by Kheiron Medical Technologies and HeartFlow. PL has/had grants/sponsored research agreements from Radiomics SA, Convert Pharmaceuticals SA and LivingMed Biotech srl. He received a presenter fee and/or reimbursement of travel costs/consultancy fee (in cash or in kind) from Astra Zeneca, BHV srl, and Roche. PL has/had minority shares in the companies Radiomics SA, Convert pharmaceuticals SA, Comunicare SA, LivingMed Biotech srl, and Bactam srl. PL is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248 and PCT/NL2014/050728), licensed to Radiomics SA; one issued patent on mtDNA (PCT/EP2014/059089), licensed to ptTheragnostic/DNAmito; one granted patent on LSRT (PCT/ P126537PC00, US patent No 12 102 842), licensed to Varian; one issued patent on Radiomic signature of hypoxia (US patent No 11 972 867), licensed to a commercial entity; one issued patent on Prodrugs (WO2019EP64112) without royalties; one non-issued, non-licensed patents on Deep Learning-Radiomics (N2024889) and three non-patented inventions (softwares) licensed to ptTheragnostic/DNAmito, Radiomics SA and Health Innovation Ventures. ARP serves as advisor for mGeneRX in exchange for equity. JM receives royalties from GE, research grants from Siemens and is unpaid consultant for Nuance. HCW owns minority shares in the company Radiomics SA. JWG serves on several radiology society AI committees. LR advises an AI startup Neurlamind. CPL is a shareholder and advisor to Bunker Hill Health, GalileoCDS, Sirona Medical, Adra, and Kheiron Medical. He serves as a board member of Bunker Hill Health and a shareholder of whiterabbit.ai. He has served as a paid consultant to Sixth Street and Gilmartin Capital. His institution has received grants or gifts from Bunker Hill Health, Carestream, CARPL, Clairity, GE Healthcare, Google Cloud, IBM, Kheiron, Lambda, Lunit, Microsoft, Philips, Siemens Healthineers, Stability.ai, Subtle Medical, VinBrain, Visiana, Whiterabbit.ai, the Lowenstein Foundation, and the Gordon and Betty Moore Foundation. GSC is a statistics editor for the BMJ and a National Institute for Health and Care Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, or the Department of Health and Social Care. All other authors declare no competing interests.
Figures



References
-
- Lekadir K, Quaglio G, Tselioudis Garmendia A, Gallin C. Artificial intelligence in healthcare—Applications, risks, and ethical and societal impacts. European Parliament, Directorate-General for Parliamentary Research Services, 2022.
Grants and funding
LinkOut - more resources
Full Text Sources